Moreover, triple therapy with T-cell inducting vaccine, PD-1 blockade, and CD40 agonist significantly promoted anti-tumor T cell immunity, marked by elevated infiltration of IFNγ-, TNFα-, and granzyme B-secreting effector T cells (121). Here, CD40 is linked to neoplasm.